Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D.A. Stevens

Rapid and Durable Responses With the Syk/Jak Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination With Rituximab

Hematological Oncology

English

Interactions of Glucocorticoids and Β2-Agonists

European Respiratory Journal

English

Related publications

Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients With Relapsed or Refractory B-Cell Malignancies: Results of a Phase I Study

American Journal of Hematology

Hematology

2019

English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

English

Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma

Hematological Oncology

English

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

English

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

American Journal of Hematology

Hematology

2019

English

Phase I Study of CC-486 Alone and in Combination With Carboplatin or Nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors

Clinical Cancer Research

Cancer Research

Oncology

2018

English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

English

Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D.A. Stevens

Rapid and Durable Responses With the Syk/Jak Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination With Rituximab

Interactions of Glucocorticoids and Β2-Agonists

Related publications

Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients With Relapsed or Refractory B-Cell Malignancies: Results of a Phase I Study

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

Phase I Study of CC-486 Alone and in Combination With Carboplatin or Nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia